Open AccessComparison of Intratesticular Testosterone between Men Receiving Nasal, Intramuscular, and Subcutaneous Pellet Testosterone Therapy: Evaluation of Data from Two Single-Center Randomized Clinical Trials
Author(s) -
Parris Diaz,
Rohit Reddy,
Rubén Blachman-Braun,
Isaac Zucker,
Alexandra Dullea,
Daniel González,
Eliyahu Kresch
Publication year - 2023
Publication title -
the world journal of men's health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 10
eISSN - 2287-4690
pISSN - 2287-4208
DOI - 10.5534/wjmh.210261
Subject(s) - testosterone (patch) , medicine , randomized controlled trial , intramuscular injection , infertility , urology , endocrinology , biology , pregnancy , genetics
Testosterone replacement therapy (TRT) can potentially cause decreased spermatogenesis and subsequent infertility. Recent studies have suggested that 17-hydroxyprogesterone (17-OHP) is a reliable surrogate for intratesticular testosterone (ITT) that is essential for spermatogenesis. We evaluated data from two ongoing open-label, randomized, two-arm clinical trials amongst different treatment preparations (Trial I) subcutaneous testosterone pellets (TP) and (Trial II) intranasal testosterone (NT) or intramuscular testosterone cypionate (TC).